当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Lucinei Roberto Oliveira, Andrielle Castilho-Fernandes and Alfredo Ribeiro-Silva
Oral Squamous Cell Carcinoma (OSCC) is the most frequent malignant tumor of the oral cavity, exhibiting a heterogeneous behavior. Because the mortality rate for this tumor has essentially remained unchanged over the last few decades, the need exists for more reliable prognostic factors in OSCC. The objective of this review was to examine the relevance of CD44 expression on the prognosis of OSCC patients through a critical analysis of the most significant current scientific literature on this subject. We found that most investigations of CD44 expression in OSCC over the years have demonstrated some prognostic influence, although there were significant differences among the studies. Certain studies have also demonstrated that CD44 may be an important biomarker of Cancer Stem Cells (CSCs) in OSCC. However, as with the discrepancies regarding the true prognostic value of CD44 in OSCC, some studies have indicated that CD44 might be limited in the identification of oral CSCs. Thus, according to our findings, additional and more standardized research should be conducted to validate the CD44 molecule as a reliable biomarker of prognosis and of CSCs in OSCC.